Purpose: To evaluate the rotational stability and visual performance of the enVista toric intraocular lens (IOL) (MX60ET) in cataract patients with pre-existing astigmatism. Setting: 6 US sites. Design: Prospective, multicenter. Methods: Cataract patients ≥18 years with pre-existing astigmatism (0.77 D to 4.53 D) underwent phacoemulsification and implantation of enVista toric IOL (MX60ET). Outcome measures were the proportion of patients with absolute IOL axis rotation of ≤5°, uncorrected and corrected distance visual acuities (UDVA and CDVA) at 4 m, uncorrected intermediate visual acuity (UIVA) at 66 cm, manifest refraction, and adverse events (AEs). The patients were followed up on Days 1–2, 7–14, 30–60, and 120–180. Results: Mean astigmatism of 101 eyes (101 subjects) reduced from 1.47 ± 0.64 D preoperatively to 0.38 ± 0.38 D at Days 120-180 (p <0.001) with 88.1% (N=89/101) of eyes achieving astigmatism within 0.75 D. Mean postoperative UDVA and UIVA were 0.10 ± 0.16 and 0.25 ± 0.15 logMAR respectively. While 79.2% (N=80/101) of patients had postoperative UDVA of 20/32 or better, 63.9% (N=62/97) had UIVA of 20/40 or better. The mean toric IOL rotation from the operative visit to Days 30-60 was 1.97 ± 2.06° with 97.4% (N=74/76) of eyes showing toric IOL rotation of 5˚ or less. Conclusion: The enhanced enVista toric IOL (MX60ET) demonstrated excellent rotational stability and astigmatic outcomes indicating good efficacy of the IOL for the correction of astigmatism during cataract surgery.
No takes yet. Share an insight, caveat, or question.
Wiley et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: